Table 4.
Anti-cancer MSCs in registered clinical trials (Clinicaltrials. gov, National Institutes of Health) as of August 2021.
| Cells | Tumors | Phase | Status | NCT | Location |
|---|---|---|---|---|---|
| Ah-BMSCs | Prostate Cancer | Phase 1 (N=7) | Terminated | NCT01983709 | Maryland, US |
| MSCs | Ovarian cancer | Phase 1 (N=5) | Completed | NCT02530047 | Texas, US |
| HB-adMSCs | Pancreatic cancer | Not available | Not available | NCT04087889 | Texas, US |
| Hematological Malignancies | Phase 1 (N=6) | Completed | NCT03106662 | Ankara, Turkey | |
| Hematological Malignancies | Phase 1 (N=30) | Completed | NCT00504803 | Liege, Belgium | |
| Head and neck cancer | Not applicable (N=20) | Recruiting | NCT02331134 | Colorado, US | |
| MSCs | Ovarian | Phase 1 Phase 2 (N=57) |
Recruiting | NCT02068794 | Minnesota, US |
| Head and neck cancer | Phase 2 (N=120) | Recruiting | NCT04776538 | Copenhagen, Denmark | |
| Head and neck cancer | Phase 1 (N=12) | Unknown | NCT02079324 | Seoul, Korea | |
| Leukemia | Phase 1 (N=98) | Completed | NCT00498316 | Texas, US |
Ah-BMSCs, allogeneic human bone marrow-derived mesenchymal stem cells; HB-adMSCs, allogeneic adipose-derived mesenchymal stem cells.